← Back to Search

Procedure

Erbium plus cosmetics plus Impact for Pigmentation

N/A
Waitlist Available
Research Sponsored by Alma Lasers Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a special laser treatment combined with a device that helps skin absorb treatments better and some skincare products. It aims to improve wrinkles, acne scars, and pigmented skin. The laser helps the skin heal and produce new collagen, while the device and products enhance the overall effect.

Eligible Conditions
  • Wrinkles
  • Acne Scars
  • Pigmentation

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinical Photographs to determine improvement of appearance

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Active Control
Group I: Erbium plus cosmetics plus ImpactActive Control1 Intervention
Erbium 2940 plus cosmetics plus Impact Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
Group II: Erbium 2940 plus cosmeticsActive Control1 Intervention
Erbium 2940 plus cosmetics Patient shall be treated with erbium 2940nm laser, cosmetics
Group III: Erbium 2940 plus cosmetics plus ImpactActive Control1 Intervention
Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
Group IV: Erbium 2940nm plus cosmeticsActive Control1 Intervention
Patients shall be treated with Erbium 2940nm laser plus cosmetics only.

Find a Location

Who is running the clinical trial?

Alma Lasers Inc.Lead Sponsor
5 Previous Clinical Trials
264 Total Patients Enrolled
~2 spots leftby Nov 2025